Arkolith/Insider Trading/PRLD/Form 4

Vaddi Krishna

CEO, DirectorPrelude Therapeutics Inc (PRLD) · full profile →Form 4 · filed Mar 18, 2025
Net Buying
Open-Market Buys
$29K
Open-Market Sells
$0
Net Open-Market Flow
$29K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 17, 2025Buy(P)9K$0.75$7K1.3M
Mar 14, 2025Buy(P)30K$0.75$22K1.3M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-002541) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML